|
π
|
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
12 auth.
S. Tyring,
A. Gottlieb,
K. Papp,
K. Gordon,
C. Leonardi,
Andrea T Wang,
...
D. Lalla,
M. Woolley,
A. Jahreis,
R. Zitnik,
D. Cella,
R. Krishnan
|
10 |
2006 |
10
π
|
|
π
|
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
24 auth.
D. Khanna,
C. Denton,
A. Jahreis,
J. Laar,
T. Frech,
Marina E Anderson,
M. Baron,
L. Chung,
G. Fierlbeck,
S. Lakshminarayanan,
...
Y. Allanore,
J. Pope,
G. Riemekasten,
V. Steen,
U. MuΜller-Ladner,
R. Lafyatis,
Giuseppina Stifano,
H. Spotswood,
Haiyin Chen-Harris,
S. Dziadek,
A. Morimoto,
T. Sornasse,
J. Siegel,
D. Furst
|
8 |
2016 |
8
π
|
|
π
|
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
16 auth.
D. Khanna,
Celia J. F. Lin,
D. Furst,
J. Goldin,
G. Kim,
M. Kuwana,
Y. Allanore,
M. Matucci-Cerinic,
O. Distler,
Y. Shima,
...
J. V. van Laar,
H. Spotswood,
Bridget Wagner,
J. Siegel,
A. Jahreis,
C. Denton
|
8 |
2020 |
8
π
|
|
π¬
|
Integrated safety in tocilizumab clinical trials
M. Schiff,
J. Kremer,
A. Jahreis,
E. Vernon,
J. Isaacs,
R. V. van Vollenhoven
|
8 |
2011 |
8
π¬
|
|
π’
|
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
7 auth.
S. Tyring,
K. Gordon,
Y. Poulin,
R. Langley,
A. Gottlieb,
M. Dunn,
...
A. Jahreis
|
8 |
2007 |
8
π’
|
|
π
|
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
20 auth.
D. Khanna,
C. Denton,
Celia J. F. Lin,
J. V. van Laar,
T. Frech,
Marina E Anderson,
M. Baron,
L. Chung,
G. Fierlbeck,
S. Lakshminarayanan,
...
Y. Allanore,
J. Pope,
G. Riemekasten,
V. Steen,
U. MuΜller-Ladner,
H. Spotswood,
L. Burke,
J. Siegel,
A. Jahreis,
D. Furst
|
7 |
2017 |
7
π
|
|
π’
|
Etanercept treatment for children and adolescents with plaque psoriasis.
11 auth.
A. Paller,
E. Siegfried,
R. Langley,
A. Gottlieb,
D. Pariser,
I. Landells,
...
A. Hebert,
L. Eichenfield,
V. Patel,
Kara Creamer,
A. Jahreis
|
7 |
2008 |
7
π’
|
|
π
|
CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells.
9 auth.
D. Homann,
A. Jahreis,
T. Wolfe,
A. Hughes,
B. Coon,
M. V. van Stipdonk,
...
K. Prilliman,
S. Schoenberger,
M. V. von Herrath
|
7 |
2002 |
7
π
|
|
π
|
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
20 auth.
B. Combe,
A. Kivitz,
Yoshiya Tanaka,
D. M. van der Heijde,
J. A. SimΓ³n,
H. Baraf,
U. Kumar,
F. Matzkies,
B. Bartok,
L. Ye,
...
Ying Guo,
Chantal Tasset,
J. Sundy,
A. Jahreis,
M. Genovese,
N. Mozaffarian,
R. LandewΓ©,
S. Bae,
E. Keystone,
P. Nash
|
7 |
2021 |
7
π
|
|
π’
|
Patientβreported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial
7 auth.
Gerald G. Krueger,
R. G. Langley,
A. Y. Finlay,
C. E. Griffiths,
J. M. Woolley,
D. Lalla,
...
A. Jahreis
|
7 |
2005 |
7
π’
|
|
π
|
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy
7 auth.
K. Gordon,
A. Gottlieb,
C. Leonardi,
B. Elewski,
Andrea T Wang,
A. Jahreis,
...
R. Zitnik
|
7 |
2006 |
7
π
|
